Central Nervous System Cancer
646 clinical trials
531 cell line models
2 approved drugs
Central Nervous System Cancer
Molecular Synopsis
Drugs and clinical candidates

2 drugs have received FDA approval for Central Nervous System Cancer:

  • Methotrexate Sodium
  • Uridine Triacetate

198 drugs have a clinical trial registered for Central Nervous System Cancer.

4219 compounds have been tested in Central Nervous System Cancer (3038 <= 500nM potency).

Sources: cancer.gov, clinicaltrials.gov, ChEMBL.

Clinical trials
There are 646 clinical trials for Central Nervous System Cancer, 437 of which have one or more drug interventions, 209 with no drug intervention.
Cell line models

There are 531 Cell Line Models for Central Nervous System Cancer.

Source: COSMIC
Cell line models

Please note the mappings below are based on an imperfect algorithm. If you notice any anomalies please report them to us.

The following terms have been mapped from clinicaltrials.gov mesh condition terms to Central Nervous System Cancer:
  • Nerve Sheath Neoplasms
  • Neoplasms, Nerve Tissue
  • Central Nervous System Neoplasms
  • Nervous System Neoplasms
  • Peripheral Nervous System Neoplasms
The following terms have been mapped from cancer.gov to Central Nervous System Cancer:
  • Acute lymphoblastic leukemia that has spread to the central nervous system, or to prevent it from spreading there
  • Cardiac (heart) or central nervous system toxicity or other serious side effects within 4 days of ending treatment with fluorouracil or capecitabine